Lei Xiao

Amministratore Delegato presso Innovative Cellular Therapeutics Co., Ltd.

Health Technology

Profilo

Lei Xiao is the founder of Innovative Cellular Therapeutics Co., Ltd.
He holds the titles of Chairman, Chief Executive, and Scientific Officer, which he has held since the company's founding in 2009.

Posizioni attive di Lei Xiao

Società	Posizione	Inizio
Innovative Cellular Therapeutics Co., Ltd. Innovative Cellular Therapeutics Co., Ltd. BiotechnologyHealth Technology Innovative Cellular Therapeutics Co., Ltd. is a Chinese private clinical stage biotechnology company headquartered in an undisclosed location. Innovative Cellular Therapeutics is focused on the development of cellular immunotherapies for the treatment of solid tumors, using their unique CoupledCAR® technology platform. The company has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and prostate cancer, and has a broad pipeline of CAR-T candidates targeting additional solid tumors. The company was founded in 2009 by Zhao Wu and Lei Xiao, with Lei Xiao serving as the CEO since then.	Amministratore Delegato	01/01/2009

Tutte le posizioni attive di Lei Xiao

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Lei Xiao

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	1
Innovative Cellular Therapeutics Co., Ltd. Innovative Cellular Therapeutics Co., Ltd. BiotechnologyHealth Technology Innovative Cellular Therapeutics Co., Ltd. is a Chinese private clinical stage biotechnology company headquartered in an undisclosed location. Innovative Cellular Therapeutics is focused on the development of cellular immunotherapies for the treatment of solid tumors, using their unique CoupledCAR® technology platform. The company has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and prostate cancer, and has a broad pipeline of CAR-T candidates targeting additional solid tumors. The company was founded in 2009 by Zhao Wu and Lei Xiao, with Lei Xiao serving as the CEO since then.	Health Technology